Serious bleeding is a major cause of morbidity and mortality worldwide and outcomes are linked to how quickly hemostasis can be achieved. Cayuga Biotech's mission is to harness the potential of polyphosphate to address uncontrolled bleeding episodes. Our first in class drug, CAY001, is in preclinical development and has been designed to accelerate control of bleeding across multiple underlying causes, including:
Platelet dysfunction and orphan bleeding disorders
Excessive bleeding is a global threat which can affect all populations, but is especially critical for patients on anticoagulant therapy or those who have a rare bleeding disorder. Across all sources of bleeding, the probability of death increases 1 % for every 3 minutes of uncontrolled hemorrhage, meaning that rapid intervention is critical to survival.
CAY001 is a first-in-class drug which aims to accelerate the body's natural clotting response even in patients with compromised platelet function. Unlike natural platelets, CAY001 is can be mass-manufactured, is stable at room temperature, and does not require type matching, allowing it to be deployed with first responders.
Small chain polyphosphate (polyP) is released from platelets upon injury. This natural polymer is rapidly metabolized within in-vivo models and has been show to accelerate clot formation within in-vitro models. Cayuga Biotech is developing a novel formulation of polyP (CAY001) with the aim of improving the in-vivo stability and potency of polyP in accelerating thrombin production and clot formation at injury sites without inducing unwanted clotting.
Kudela D. “Restoring Hemostasis Following Injury Using Polyphosphate-Coated Silica Nanoparticles.” The Federation of American Societies for Experimental Biology Journal. 2017, 31, 978.13.
Kudela D., Smith S.A., May-Masnou A., Braun, G.B., Pallaoro, A., Nguyen, C.K., Chuong, T.T., Nownes, S., Allen, R., Parker, N.R., Rashidi, H.H., Morrissey, J.H., Stucky, G.D. “Clotting Activity of Polyphosphate-Functionalized Silica Nanoparticles.” Angewandte Chemie International Edition. 2015, 54, 4018-4022.
Smith S.A., Choi S.H., Davis-Harrison R., Huyck J., Boettcher J., Rienstra C.M., Morrissey J.H. “Polyphosphate exerts differential effects on blood clotting, depending on polymer size.” Blood. 2010, 116, 4353-4359.
Smith S.A., Morrissey J.H. “Polyphosphate as a general procoagulant agent.” Journal of Thrombosis and Haemosasis. 2008, 6, 1750-1756.
23 years FDA experience
President, Tracy BioConsulting
Harvard Medical School,
Department of Emergency Medicine
Professor of Anesthesiology,
Critical Care, and Surgery
Former CEO Redwood Bioscience
Partner, Thomas, McNerney & Partners
CEO Neuron23 Inc.,
Former CEO True North Therapeutics, iPierian, CytomX
Biological Chemistry Department,
University of Michigan Medical School
National Academy of Science
Materials Department, UCSB
Cayuga selected for DOD's Joint Warfighter Medical Research Program
Cayuga will present at IndieBio Demo Day:
Cayuga Biotech wins UC Startup Competition and is named a
finalist for the Extreme Tech Challenge in June
Cayuga Biotech named a finalist for the Army xTechSearch 3.0
Cayuga is proud to be a member of the IndieBio Accelerator program. In addition, we are collaborating with DARPA as well as the United States Army.